Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | FAP | Q12884 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360470 | 0.91 | DPP4 (0.76) | DPP4CHRM1KCNH2FAP | |
| SCHEMBL2965678 | 0.89 | DPP4 (0.66) | DPP4CHRM1FAP | |
| SCHEMBL5359579 | 0.88 | DPP4 (0.76) | DPP4CHRM1KCNH2FAP | |
| SCHEMBL5364710 | 0.87 | DPP4 (0.66) | DPP4CHRM1KCNH2FAP | |
| SCHEMBL13200817 | 0.84 | DPP4 (0.58) | DPP4CHRM1FAP | |
| SCHEMBL5358375 | 0.84 | DPP4 (0.68) | DPP4CHRM1KCNH2FAP | |
| SCHEMBL5364481 | 0.84 | DPP4 (0.77) | DPP4CHRM1FAP | |
| SCHEMBL5353869 | 0.83 | DPP4 (0.64) | DPP4CHRM1FAP | |
| SCHEMBL5353856 | 0.83 | DPP4 (0.66) | DPP4CHRM1KCNH2FAP | |
| SCHEMBL5353091 | 0.83 | DPP4 (0.72) | DPP4CHRM1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | disclosed |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 515/4885KCNH2 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.